zurück

Faricimab (neovascular age-related macular degeneration (nAMD))

 

Subject:

  • Active Substance: Faricimab
  • Name: Vabysmo®
  • Therapeutic area: Neovascular age-related macular degeneration (nAMD)
  • Pharmaceutical company: Roche Pharma AG

 

Time table:

  • Start: 15.10.2022
  • Publication of assessment: 16.01.2023
  • End of public hearing: 06.02.2023
  • Final decision by G-BA: beginning of April 2023

 

Comparative therapy:

  • Ranibizumab or aflibercept